X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2936) 2936
Book Review (638) 638
Publication (367) 367
Newsletter (251) 251
Book Chapter (22) 22
Book / eBook (13) 13
Conference Proceeding (6) 6
Dissertation (2) 2
Magazine Article (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2675) 2675
humans (2407) 2407
pharmacology & pharmacy (1446) 1446
cytochrome p-450 (1346) 1346
male (930) 930
female (858) 858
cytochrome p-450 enzyme system - metabolism (817) 817
metabolism (798) 798
cytochrome p-450 enzyme system - genetics (775) 775
animals (760) 760
cytochrome p450 (662) 662
adult (606) 606
pharmacogenetics (603) 603
physiological aspects (595) 595
aryl hydrocarbon hydroxylases - genetics (562) 562
pharmacokinetics (553) 553
enzymes (511) 511
genotype (507) 507
middle aged (500) 500
cytochrome p-450 cyp2b6 (494) 494
research (494) 494
toxicology (479) 479
genetic aspects (447) 447
analysis (412) 412
liver (383) 383
drug interactions (380) 380
human liver-microsomes (367) 367
oxidoreductases, n-demethylating - genetics (359) 359
metabolites (352) 352
in-vitro (349) 349
expression (335) 335
genetic polymorphisms (312) 312
polymorphism, genetic (312) 312
drug metabolism (309) 309
aged (297) 297
biochemistry & molecular biology (289) 289
cyp2b6 (286) 286
aryl hydrocarbon hydroxylases - metabolism (281) 281
gene expression (261) 261
induction (258) 258
polymorphism (251) 251
pharmacology (250) 250
cytochrome (245) 245
drugs (240) 240
cytochrome p-450 cyp3a - genetics (238) 238
cancer (234) 234
microsomes, liver - enzymology (233) 233
polymorphism, single nucleotide (231) 231
genes (227) 227
pharmacology/toxicology (219) 219
rats (218) 218
cytochrome p-450 cyp3a - metabolism (216) 216
article (213) 213
microsomes, liver - metabolism (213) 213
mice (206) 206
biotransformation (203) 203
young adult (203) 203
liver - metabolism (202) 202
pregnane-x-receptor (201) 201
liver - enzymology (198) 198
constitutive androstane receptor (193) 193
alleles (192) 192
health aspects (192) 192
hydroxylation (191) 191
rna, messenger - metabolism (187) 187
cells, cultured (186) 186
dose-response relationship, drug (185) 185
efavirenz (185) 185
inhibition (185) 185
kinetics (183) 183
hiv infections - drug therapy (182) 182
cytochrome p-450 cyp2b6 - genetics (177) 177
drug-metabolism (176) 176
care and treatment (174) 174
hepatocytes - drug effects (174) 174
oxidoreductases, n-demethylating - metabolism (172) 172
genetic research (170) 170
cytochrome p-450 enzyme system - biosynthesis (169) 169
identification (169) 169
drug therapy (168) 168
toxicity (166) 166
adolescent (165) 165
gene-expression (162) 162
oncology (160) 160
cytochrome p-450 cyp3a (159) 159
human hepatocytes (159) 159
cyp3a4 (157) 157
polymorphisms (157) 157
cytochrome p-450 cyp2c19 (156) 156
cytochrome p-450 enzyme inhibitors (156) 156
hepatocytes - metabolism (156) 156
phenotype (153) 153
pharmaceutical preparations - metabolism (152) 152
cytochrome p-450 cyp2d6 - genetics (151) 151
p-glycoprotein (149) 149
gene frequency (147) 147
clopidogrel (146) 146
cyp2c19 (146) 146
antiviral agents (140) 140
biomedicine (140) 140
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3199) 3199
Chinese (5) 5
German (5) 5
Japanese (3) 3
Russian (2) 2
Spanish (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemistry, ISSN 0006-2960, 02/2018, Volume 57, Issue 5, pp. 817 - 826
Human hepatic cytochromes P450 (CYP)' are integral to xenobiotic metabolism. CYP2B6 is a major catalyst of biotransformation of environmental toxicants,... 
SIDE-CHAINS | ACTIVE-SITE | STRUCTURAL BASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ESCHERICHIA-COLI | MAMMALIAN CYTOCHROME-P450 | LIVER-MICROSOMES | HUMAN CYTOCHROME-P450 2B6 | SITE-DIRECTED MUTAGENESIS | OXIDATIVE-METABOLISM | DRUG-METABOLISM | Cytochrome P-450 CYP2B1 - genetics | Aniline Compounds | Humans | Aryl Hydrocarbon Hydroxylases - genetics | NADPH Oxidases - metabolism | Substrate Specificity | Cytochrome P-450 Enzyme Inhibitors - metabolism | Structure-Activity Relationship | Environmental Pollutants - metabolism | Cytochromes b5 - metabolism | Cytochrome P-450 CYP2B6 - metabolism | Cytochrome P-450 CYP2B6 Inhibitors - metabolism | Cytochrome P-450 CYP2B6 - drug effects | Hydrocarbons, Halogenated - metabolism | Cytochrome P-450 CYP2B1 - chemistry | Cytochrome P450 Family 2 - genetics | Inhibitory Concentration 50 | Cytochrome P-450 CYP2B1 - metabolism | Molecular Structure | Aryl Hydrocarbon Hydroxylases - chemistry | Benzene Derivatives - pharmacology | Cytochrome P450 Family 2 - antagonists & inhibitors | Recombinant Proteins - metabolism | Rabbits | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Mutagenesis, Site-Directed | Oxidation-Reduction | Cytochrome P-450 CYP2B6 - genetics | Halogenated Diphenyl Ethers - pharmacology | Rats | Cytochrome P450 Family 2 - chemistry | Cytochrome P-450 CYP2B1 - antagonists & inhibitors | Aryl Hydrocarbon Hydroxylases - metabolism | Cytochrome P-450 CYP2B6 Inhibitors - pharmacology | Halogenated Diphenyl Ethers - metabolism | Cytochrome P-450 Enzyme Inhibitors - pharmacology | Animals | Cytochrome P450 Family 2 - metabolism | Alkylation - drug effects | Cytochrome P-450 CYP2B6 - chemistry | Amino Acid Substitution | Research | Chemical properties | Aniline | Cytochrome P-450 | Index Medicus
Journal Article
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2014, Volume 69, Issue 8, pp. 2175 - 2182
Efavirenz is widely prescribed for HIV-1 infection, and CYP2B6 polymorphisms 516G -> T and 983T -> C define efavirenz slow metabolizer genotypes. To identify... 
Non-nucleoside reverse transcriptase inhibitor | Pharmacogenetics | Pharmacokinetics | Antiretroviral therapy | Pharmacogenomics | INFECTIOUS DISEASES | antiretroviral therapy | INITIAL TREATMENT | MICROBIOLOGY | RANDOMIZED CONTROLLED-TRIAL | ANTIRETROVIRAL REGIMENS | DRUG EFAVIRENZ | INDIVIDUALS | IN-VITRO | pharmacogenomics | THERAPY | GENE | pharmacokinetics | PHARMACOLOGY & PHARMACY | ASSOCIATION | pharmacogenetics | non-nucleoside reverse transcriptase inhibitor | HIV Infections - blood | European Continental Ancestry Group - genetics | Prospective Studies | Reverse Transcriptase Inhibitors - blood | Cytochrome P-450 CYP2A6 - genetics | Cytochrome P-450 CYP2B6 - genetics | HIV-1 - drug effects | Cytochrome P-450 CYP2B6 Inducers - blood | Humans | Benzoxazines - metabolism | Male | Gene Dosage | Benzoxazines - therapeutic use | Cytochrome P-450 CYP2B6 Inducers - therapeutic use | Glucuronosyltransferase - genetics | Secondary Metabolism - drug effects | Adult | Anti-HIV Agents - therapeutic use | Benzoxazines - blood | Female | HIV Infections - drug therapy | Polymorphism, Single Nucleotide | African Continental Ancestry Group - genetics | Reverse Transcriptase Inhibitors - therapeutic use | Antiretroviral drugs | Chemotherapy | Adults | Pharmacology | Human immunodeficiency virus--HIV | Genomics | Index Medicus | Original Research
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 09/2016, Volume 119, Issue 3, pp. 284 - 290
Cytochrome P450 ( CYP ) activity can be assessed using a ‘cocktail’ phenotyping approach. Recently, we have developed a cocktail (Geneva cocktail) which... 
2D6 | PARAXANTHINE | BUPROPION | IN-VIVO | PHARMACOLOGY & PHARMACY | TOXICOLOGY | FLURBIPROFEN | METABOLIZING-ENZYMES | COOPERSTOWN 5+1 COCKTAIL | ORAL-CONTRACEPTIVES | P-GLYCOPROTEIN | Caffeine - administration & dosage | Humans | Midazolam - administration & dosage | Male | Genotyping Techniques | Cytochrome P-450 CYP2B6 - metabolism | Terfenadine - administration & dosage | Caffeine - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Cytochrome P-450 CYP3A - genetics | Dried Blood Spot Testing - methods | Cytochrome P-450 CYP1A2 - genetics | Flurbiprofen - administration & dosage | Adult | Female | Dextromethorphan - pharmacokinetics | Cytochrome P-450 CYP2C9 - metabolism | Terfenadine - pharmacokinetics | Bupropion - pharmacokinetics | Cytochrome P-450 CYP2D6 - genetics | Flurbiprofen - pharmacokinetics | Cytochrome P-450 CYP2B6 - genetics | Omeprazole - administration & dosage | Cytochrome P-450 CYP2C19 - genetics | Terfenadine - analogs & derivatives | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP1A2 - metabolism | Bupropion - administration & dosage | Cytochrome P-450 CYP2C9 - genetics | Cross-Over Studies | Phenotype | Cytochrome P-450 CYP3A - metabolism | Adolescent | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 Enzyme System - genetics | Cytochrome P-450 CYP2C19 - metabolism | Dextromethorphan - administration & dosage | Medical examination | Drug interactions | Analysis | Methods | Blood | Cytochrome P-450 | Confidence intervals | Cytochrome | Prescription drugs | Drug dosages | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2016, Volume 44, Issue 1, pp. 151 - 161
Efavirenz (EFV) is principally metabolized by CYP2B6 to 8-hydroxy-efavirenz (8OH-EFV) and to a lesser extent by CYP2A6 to 7-hydroxy-efavirenz (7OH-EFV). So... 
400 MG | TRIAL | THERAPY | CYP2B6 | HIV | MORPHINE | LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | MORPHINE-6-GLUCURONIDE | PHARMACOLOGY & PHARMACY | ACTIVE-TRANSPORT | BLOOD-BRAIN-BARRIER | Neurotoxicity Syndromes - genetics | Reverse Transcriptase Inhibitors - blood | Humans | Anti-HIV Agents - cerebrospinal fluid | Glucuronides - cerebrospinal fluid | Cytochrome P-450 CYP2B6 - metabolism | Glucuronides - blood | Reverse Transcriptase Inhibitors - adverse effects | Tandem Mass Spectrometry | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - urine | Cytochrome P-450 CYP3A - genetics | Benzoxazines - pharmacokinetics | Sulfates - blood | HIV Infections - diagnosis | Benzoxazines - blood | Anti-HIV Agents - blood | Reverse Transcriptase Inhibitors - urine | Metabolic Detoxication, Phase II | Hydroxylation | Risk Assessment | Cytochrome P-450 CYP2A6 - genetics | Cytochrome P-450 CYP2B6 - genetics | Anti-HIV Agents - adverse effects | Benzoxazines - cerebrospinal fluid | Benzoxazines - adverse effects | Cytochrome P-450 CYP2A6 - metabolism | Genotype | Glucuronides - urine | Anti-HIV Agents - urine | Reverse Transcriptase Inhibitors - cerebrospinal fluid | Sulfates - cerebrospinal fluid | Metabolomics - methods | Neurotoxicity Syndromes - etiology | Phenotype | Sulfates - urine | Cytochrome P-450 CYP3A - metabolism | Anti-HIV Agents - pharmacokinetics | Metabolic Detoxication, Phase I | Neurotoxicity Syndromes - metabolism | HIV Infections - drug therapy | HIV Infections - metabolism | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 10/2015, Volume 98, Issue 4, pp. 406 - 416
Journal Article